Recursion Pharmaceuticals CFO Ben Taylor to Join Exscientia
Recursion Pharmaceuticals (RXRX) Bold Acquisition Makes It a Leader in AI Drug Discovery
Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
Express News | Recursion Announces First Patient Dosed in Phase 1/2 Clinical Study of REC-1245, a Potential First-in-Class, Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Nvidia Bought 6 Artificial Intelligence (AI) Stocks, but This 1 Has Soared the Most
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday